Human medicines European public assessment report (EPAR): Pifeltro, doravirine, Date of authorisation: 22/11/2018, Revision: 12, Status: Authorised

Human medicines European public assessment report (EPAR): Opuviz, aflibercept, Date of authorisation: 13/11/2024, Revision: 6, Status: Authorised

Clinical Trials Information System (CTIS) bitesize talk: CTIS training environment and role management, Online, European Medicines Agency, Amsterdam, the Netherlands, Broadcast, from 18 November 2026, 15:30 (CET) to 18 November 2026, 17:00 (CET)

Human medicines European public assessment report (EPAR): Siklos, hydroxycarbamide, Date of authorisation: 29/06/2007, Revision: 32, Status: Authorised

Human medicines European public assessment report (EPAR): Pyrukynd, mitapivat, Date of authorisation: 09/11/2022, Revision: 4, Status: Authorised

Human medicines European public assessment report (EPAR): Eltrombopag Accord, eltrombopag, Date of authorisation: 28/03/2025, Revision: 7, Status: Authorised

Human medicines European public assessment report (EPAR): Febuxostat Viatris (previously Febuxostat Mylan), febuxostat, Date of authorisation: 15/06/2017, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Fasenra, benralizumab, Date of authorisation: 08/01/2018, Revision: 17, Status: Authorised

Human medicines European public assessment report (EPAR): Diacomit, stiripentol, Date of authorisation: 03/01/2007, Date of refusal: 11/02/2009, Revision: 21, Status: Authorised

Agenda - EMA Methodology Working Party (MWP) interested parties meeting 2026